Allspring Global Investments Holdings LLC Has $67.64 Million Holdings in Bristol Myers Squibb Company $BMY

Allspring Global Investments Holdings LLC lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,095,654 shares of the biopharmaceutical company’s stock after purchasing an additional 57,224 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Bristol Myers Squibb were worth $67,635,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Swiss RE Ltd. bought a new position in Bristol Myers Squibb during the fourth quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter valued at about $25,000. Bayban acquired a new position in Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb during the fourth quarter worth about $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a report on Monday, July 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.25.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY.
• Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself.
• Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $60.71 on Friday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The stock has a market capitalization of $123.97 billion, a P/E ratio of 17.05, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The stock has a fifty day moving average of $57.02 and a 200-day moving average of $57.78.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period last year, the company earned $1.80 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.